Phase II trial of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by postoperative gemcitabine (GEM) in patients (pts) with borderline resectable pancreatic ductal adenocarcinomas (BR-PDAC).

被引：0
|
作者：
Yoo, Changhoon
Kim, Kyu-Pyo
Song, Ki Byung
Lee, Sang Soo
Park, Do Hyun
Song, Tae Jun
Lee, Seung Soo
Park, Jin-Hong
Hwang, Dae Wook
Lee, Jae Hoon
Shin, Sang Hyun
Shin, Eunseon
Ryoo, Baek-Yeol
Kim, Song Cheol
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol, Seoul, South Korea
[4] Asan Med Ctr, Dept Radiol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[6] Asan Med Ctr, Dept Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.2019.37.4_suppl.342
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
342
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial.
    Lee, Dong Ho
    Lee, Jae Young
    Lee, Sang Hyub
    Jang, Jin-Young
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 670 - 670
  • [32] Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma
    Aybar, Pablo Emilio Serrano
    Herman, Joseph M.
    Zalupski, Mark
    Kim, Edward Jae-Hoon
    Ben-Josef, Edgar
    Bekaii-Saab, Tanios S.
    Wolfgang, Christopher Lee
    Laheru, Daniel A.
    Moore, Malcolm J.
    Dawson, Laura A.
    Ringash, Jolie
    Wei, Alice Chia-chi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [33] Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the CISPD-4 study)
    Chen, Yiwen
    Guo, Chengxiang
    Bai, Xueli
    Gao, Shunliang
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Que, Risheng
    Li, Xiang
    Liang, Tingbo
    Wu, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [34] Randomized phase II trial of neoadjuvant chemotherapy with modified FOLFIRINOX versus modified FOLFIRINOX and PD-1 antibody for borderline resectable and locally advanced pancreatic cancer (the CISPD-4 study)
    Chen, Y.
    Guo, C.
    Li, X.
    Gao, S.
    Shen, Y.
    Zhang, M.
    Yu, J.
    Wu, J.
    Que, R.
    Zhang, A.
    Bai, X.
    Liang, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S1443 - S1443
  • [35] Phase Ib study testing neoadjuvant transforming growth factor (TGF)-b antibody, NIS793, plus 5-fluorouracil, irinotecan, and oxaliplatin chemotherapy (FOLFIRINOX) in patients (pts) with borderline resectable (BR)/locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).
    Weekes, Colin D.
    Ting, David Tsai
    Parikh, Aparna Raj
    Ittershagen, Stacie
    Fabre, Claire
    Cremasco, Viviana
    Ruddy, David
    Liss, Andrew
    O'Shea, Aileen
    Harisinghani, Mukesh
    Piquet, Michelle
    Chang, Jonathan
    Kwak, Eunice Lee
    Ryan, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS762 - TPS762
  • [36] Quality of Life in a Multi-enter Phase II Trial of Neoadjuvant Full Dose Gemcitabine, Oxaliplatin and Radiation in Patients with Resectable or Borderline Resectable Pancreatic Adenocarcinoma
    Serrano, P. E.
    Herman, J. M.
    Laheru, D. A.
    Wolfgang, C.
    Zalupski, M. M.
    Kim, E. J.
    Bekaii-Saab, T. S.
    Moore, M. J.
    Dawson, L. A.
    Ringash, J. G.
    Wei, A. C.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S32 - S32
  • [37] Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer
    Tran, Nguyen H.
    Sahai, Vaibhav
    Griffith, Kent A.
    Nathan, Hari
    Kaza, Ravi
    Cuneo, Kyle C.
    Shi, Jiaqi
    Kim, Edward
    Sonnenday, Christopher J.
    Cho, Clifford S.
    Lawrence, Theodore S.
    Zalupski, Mark M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (01): : 124 - 133
  • [38] A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC)
    Bajor, David L.
    Lee, Ho Jun
    Selfridge, J. Eva
    Mohamed, Amr
    Conces, Madison
    Lumish, Melissa Amy
    Chakrabarti, Sakti
    Mahipal, Amit
    Anderson, Erin E.
    Donohue, Debbie
    Tirumani, Sree Harsha
    Dorth, Jennifer Anne
    Henke, Lauren E.
    Ocuin, Lee Mayer
    Ammori, John Brian
    Hardacre, Jeffrey
    Winter, Jordan Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] A multi-institutional phase II trial of preoperative full dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma
    Talamonti, MS
    Small, W
    Mulcahy, MF
    Attaluri, V
    Colletti, L
    Zalupski, MM
    Hoffman, J
    Freedman, GM
    Kinsella, TJ
    McGinn, CJ
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (02) : S13 - S13
  • [40] Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results.
    Morizane, C
    Okusaka, T
    Ito, Y
    Ueno, H
    Ikeda, M
    Takezako, Y
    Sumi, M
    Kagami, Y
    Ikeda, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 361S - 361S
12345